Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma
- 30 November 2006
- journal article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 21 (2), 333-339
- https://doi.org/10.1038/sj.leu.2404471
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cellsLeukemia, 2005
- Chemotherapy with rituximab followed by high‐dose therapy and autologous stem cell transplantation in patients with mantle cell lymphomaCancer, 2005
- The Akt-mTOR tango and its relevance to cancerCancer Cell, 2005
- Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell LymphomaJournal of Clinical Oncology, 2005
- Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinibLeukemia, 2005
- Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphomaCancer, 2004
- TOR signalling in bugs, brain and brawnNature Reviews Molecular Cell Biology, 2003
- Anti-CD20-based therapy of B cell lymphoma: state of the artLeukemia, 2002
- Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective studyLeukemia, 2002
- 4E-binding Proteins, the Suppressors of Eukaryotic Initiation Factor 4E, Are Down-regulated in Cells with Acquired or Intrinsic Resistance to RapamycinJournal of Biological Chemistry, 2002